Rabeprazole

Drugs

Volumn 55, Issue 2, 1998, Pages 261-267

  Prakash, Amitabh ^a   Faulds, Diana ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; CLARITHROMYCIN; FAMOTIDINE; HYDROGEN POTASSIUM ADENOSINE TRIPHOSPHATASE; METRONIDAZOLE; OMEPRAZOLE; PROTON PUMP; PROTON PUMP INHIBITOR; RABEPRAZOLE; RANITIDINE;

CLINICAL TRIAL; DIARRHEA; GASTROESOPHAGEAL REFLUX; HEADACHE; HELICOBACTER PYLORI; HUMAN; MALAISE; META ANALYSIS; NAUSEA; NONHUMAN; PEPTIC ULCER; RASH; REVIEW; ULCER HEALING; VERTIGO;

EID: 0031892875     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-199855020-00009     Document Type: Review

References (45)

1. +-ATPase is correlated with the rate of acid-activation of the inhibitor. Biochem Pharmacol 1990 Feb 15; 39: 661-7
2. +-ATPase is inhibited by E3810 (2-[{4-(3-methoxypropoxy)-3-methylpyridin-2-yl)-methylsulfinyl]-1H-benzi midazole, sodium) [abstract]. FASEB J 1990 Feb 26; 4: 473
3. Oketani K, Murakami M, Fujimoto M, et al. The secretion of acid from isolated rabbit gastric glands is inhibited by E3810 (2-[{4-(3-methoxypropoxy)-3-methylpyridin-2-yl}-methylsulfinyl]-1H- benzimidazole, sodium) [abstract]. FASEB J 1990 Feb 26; 4: 473
4. Shibata H, Murakami M, Fujimoto M, et al. Histamine-stimulated gastric acid secretion is inhibited in gastric fistula dogs treated with E3810 (2-[{4-(3-methoxypropoxy)-3-methylpyridin-2-yl}-methylsulfinyl]-1H- benzimidazole, sodium) [abstract]. FASEB J 1990 Feb 26; 4: 473
5. Fujisaki H, Shibata H, Oketani K, et al. Inhibitions of acid secretion by E3810 and omeprazole, and their reversal by glutathione. Biochem Pharmacol 1991 Jul 5; 42: 321-8
6. +-ATPase with extracytoplasmic thiol reagents. J Biol Chem 1997; 272: 22438-46
7. +-ATPase. Biochem Pharmacol 1995 Jun 16; 49: 1729-34
8. Morii M, Takeguchi N. The conformational state of proton pump is differently affected by omeprazole, lansoprazole and E3810 [abstract no. 1994P]. 10th World Congress on Gastroenterology 1994
9. +-ATPase inhibitors, omeprazole and E3810. J Biol Chem 1993 Oct 15; 268: 21553-9
10. Takeguchi N, Tomiyama Y, Morii M. The intracellular cycling of gastric proton pump is differently affected by E3810 and lansoprazole [abstract no. 1996P]. 10th World Congress on Gastroenterology 1994
11. Takeguchi N, Tomiyama Y, Morii M. E3810 and lansoprazole differently affect the proton pump cycling [abstract]. Z Gastroenterol 1993 Sep; 31: 579
12. Tomiyama Y, Morii M, Takeguchi N. Specific proton pump inhibitors E3810 and lansoprazole affect the recovery process of gastric secretion in rats differently. Biochem Pharmacol 1994 Nov 29; 48: 2049-55
13. +-ATPase in healthy male volunteers [abstract]. Gastroenterology 1993 Apr; 104 Suppl.: A180
14. Blanshard C, Millson C, Sercombe J, et al. The effects of rabeprazole on 24-hour intragastric acidity and plasma gastrin concentration in healthy subjects [abstract]. Gut 1996; 39 Suppl. 3: 47-8
15. Kovacs TOG, Sytnik B, Humphries TJ, et al. A low dose of a new proton pump inhibitor LY-307640 (E3810) effectively inhibits acid secretion in humans [abstract]. Gastroenterology 1996 Apr; 110 Suppl.: 161
16. + activity and nocturnal acid secretion in healthy subjects [abstract]. Gut 1996; 39 Suppl. 3: 47
17. Williams M, Sercombe J, Pounder RE. Comparison of the effects of rabeprazole and omeprazole on 24-hour intragastric acidity and plasma gastrin concentration in healthy subjects [abstract]. Am J Gastroenterol 1997; 92 (9): 1627
18. Humphries TJ, Spera A, Breiter J. Rabeprazole sodium (E3810) once daily is superior to ranitidine 150 mg QID in the healing of erosive or ulcerative gastroesophageal reflux disease [abstract]. Gastroenterology 1996 Apr; 110 Suppl.: 139
19. Robinson M, Maton PN, Rodriguez S, et al. Effects of oral rabeprazole on oesophageal and gastric pH in patients with gastro-oesophageal reflux disease. Aliment Pharmacol Ther 1997; 11: 973-80
20. Inoue M, Shirakawa T, Murakami Y, et al. Effect of a new proton pump inhibitor E3810 on intragastric pH in the patients with peptic ulcer [abstract]. Gastroenterology 1991 May; 100 Suppl.: 89
21. Takiuchi H, Asada S, Umegaki E, et al. Effects of proton pump inhibitors, omeprazole, lansoprazole and E3810, on the gastric mucin [abstract no. 1404P]. 10th World Congress on Gastroenterology 1994
22. Goto H, Sugiyama S, Tsukamoto Y, et al. Effects of two benzimidazoles as proton pump inhibitors on water immersion stress-induced gastric ulcers in rats. Arzneimittel Forschung 1991 Jun; 41: 635-7
23. Suzuki T, Tsukamoto Y, Goto H, et al. Effects of histamine-H(2)-receptor antagonists and a proton pump inhibitor on the mucosal hydroxyproline content of ethanol-HCl-induced gastric lesions in rats. Digestion 1992 Mar; 51: 161-7
24. Dammann HG, Burkhardt F. Rabeprazole does not affect endocrine function in healthy subjects [abstract]. Am J Gastroenterol 1996 Sep; 91: 1909
25. Satoh M, Tonomura H, Murakami M, et al. In vitro activity of E3810/LY307640, a novel proton pump inhibitor, against Helicobacter pylori [abstract no. 196P]. 10th World Congress on Gastroenterology 1994
26. Hirai M, Azuma T, Ito S, et al. A proton pump inhibitor, E3810, has antibacterial activity through binding to Helicobarter pylori. J Gastroenterol 1995; 30 (4): 461-4
27. Park JB, Imamura L, Kobashi K. Kinetic studies of Helicobacter pylori urease inhibition by a novel proton pump inhibitor, rabeprazole. Biol Pharm Bull 1996 Feb; 19: 182-7
28. Moore R, Bryan LE, Satoh M, et al. Anti-Helicobacter pylori activity synergy between amoxicillin and the thioether derivative of the proton pump inhibitor E3810/LY307640 [abstract no. 197P]. 10th World Congress on Gastroenterology 1994
29. Humphries TJ, Bassion S, Spanyers SA. Pilot studies on the effects of rabeprazole sodium (E3810), amoxicillin, and placebo on the eradication of H. pylori [abstract]. Am J Gastroenterol 1996 Sep; 91: 1914
30. Stack W, Atherton J, Sen AK, et al. Rabeprazole is effective when used in combination with antibiotics for the eradication of Helicobacter pylori [abstract]. Am J Gastroenterol 1997; 92 (9): 1626
31. Yasuda S, Ohnishi A, Ogawa T, et al. Pharmacokinetic properties of E3810, a new proton pump inhibitor, in healthy male volunteers. Int J Clin Pharmacol Ther 1994 Sep; 32: 466-73
32. Yasuda S, Horai Y, Tomono Y, et al. Comparison of the kinetic disposition and metabolism of E3810, a new proton pump inhibitor, and omeprazole in relation to S-mephenytoin 4′-hydroxylation status. Clin Pharmacol Ther 1995 Aug; 58: 143-54
33. Ishizaki T, Chiba K, Manabe K, et al. Comparison of the interaction potential of a new proton pump inhibitor. E3810, versus omeprazole with diazepam in extensive and poor metabolizers of S-mephenytoin 4′-hydroxylation. Clin Pharmacol Ther 1995 Aug; 58: 155-64
34. Humphries TJ, Nardi RV, Spera AC, et al. Coadministration of rabeprazole sodium (E3810) does not effect the pharmacokinetics of anhydrous theophylline or warfarin [abstract]. Gastroenterology 1996 Apr; 110 Suppl.: 138
35. Humphries TJ, Spera AC, Laurent AL. Rabeprazole sodium (E3810) 20 mg daily does not affect the pharmacokinetics of phenytoin sodium in normal volunteers [abstract]. Am J Gastroenterol 1996 Sep; 91: 1914
36. Humphries TJ, Nardi RV, Spera AC, et al. Coadministration of rabeprazole sodium (E3810) and ketoconazole results in a predictable interaction with ketoconazole [abstract]. Gastroenterology 1996 Apr; 110 Suppl.: 138
37. Humphries TJ, Nardi RV, Lazar JD, et al. Drug-drug interaction evaluation of rabeprazole sodium: a clean/expected slate? [abstract]. Gut 1996; 39 Suppl. 3: 47
38. Humphries TJ, Spera AC, Laurent AL. Coadministration of rabeprazole sodium (E3810) and digoxin results in a predictable interaction [abstract]. Am J Gastroenterol 1996 Sep; 91: 1914
39. Cloud ML, Olovich K, Enas N. LY307640 versus placebo in healing duodenal ulcers [abstract]. Gastroenterology 1995 Apr; 108 Suppl.: A73
40. Nakazawa S, Namiki M, Matsuo Y, et al. Clinical utility of E3810 for the treatment of duodenal ulcer: comparison with famotidine by multi-center double-blind study [in Japanese]. Rinsho Hyoka 1993 Dec; 21: 361-82
41. Beker JA, Dekkers CPM, Thjodleifsson B, et al. Rabeprazole sodium 20mg once daily is similar to omeprazole 20mg once daily in the healing of active duodenal ulcer [abstract]. Gastroenterology 1997 May; 112 (4): A70
42. Humphries TJ, Spera A, Breiter J, et al. Rabeprazole sodium once daily is superior to ranitidine 150mg bid in the healing of active duodenal ulcer [abstract]. Gastroenterology 1997 May; 112 (4): A154
43. Humphries TJ, Cloud ML, Enas N, et al. Rabeprazole (E3810, LY307640) achieves high rates of healing in active gastric ulcer [abstract]. Gastroenterology 1996 Apr; 110 Suppl.: 138
44. Nakazawa S, Namiki M, Matsuo Y, et al. Clinical utility of E3810 for the treatment of gastric ulcer: comparison with famotidine by multi-center double-blind study [in Japanese]. Rinsho Hyoka 1993 Dec; 21: 337-59
45. Thjodleifsson B, Dekkers CPM, Beker JA, et al. Rabeprazole sodium 20mg once daily is similar to omeprazole 20mg once daily in the treatment of erosive or ulcerative GERD [abstract]. Gastroenterology 1997 May; 112 (4): A312